Navigation Links
Bisphenol A linked to metabolic syndrome in human tissue
Date:9/4/2008

CINCINNATINew research from the University of Cincinnati (UC) implicates the primary chemical used to produce hard plasticsbisphenol A (BPA)as a risk factor for metabolic syndrome and its consequences.

In a laboratory study, using fresh human fat tissues, the UC team found that BPA suppresses a key hormone, adiponectin, which is responsible for regulating insulin sensitivity in the body and puts people at a substantially higher risk for metabolic syndrome.

Metabolic syndrome is a combination of risk factors that include lower responsiveness to insulin and higher blood levels of sugar and lipids. According to the American Heart Association, about 25 percent of Americans have metabolic syndrome. Left untreated, the disorder can lead to life-threatening health problems such as coronary artery disease, stroke and type 2 diabetes.

Nira Ben-Jonathan, PhD, and her team are the first to report scientific evidence on the health effects of BPA at environmentally relevant doses equal to "average" human exposure. Previous studies have primarily focused on animal studies and high doses of BPA.

They report their findings in the Aug. 14, 2008, online edition of the journal Environmental Health Perspectives. This scientific data comes just before a key Federal Drug Administration meeting about the safety of the chemical in consumer products scheduled for Sept. 16, 2008.

"People have serious concerns about the potential health effects of BPA. As the scientific evidence continues to mount against the chemical, it should be given serious attention to minimize future harm," says Ben-Jonathan, a professor of cancer and cell biology at UC who has studied BPA for more than 10 years.

"Experimenting with human tissue is the closest we can come to testing the effects of BPA in humans. It's a very exciting breakthrough because epidemiological studies looking at BPA effects on humans are difficult since most people have alre
'/>"/>

Contact: Amanda Harper
amanda.harper@uc.edu
513-659-6847
University of Cincinnati
Source:Eurekalert

Page: 1 2

Related biology news :

1. NTP finalizes report on Bisphenol A
2. Height linked to risk of prostate cancer development and progression
3. Hopkins researchers piece together gene network linked to schizophrenia
4. Fish cancer gene linked to pigment pattern that attracts mates
5. UNC researchers find MSG use linked to obesity
6. UCR graduate student discovers, names bacterium linked to psyllid yellows
7. Pre-cancerous condition linked to chronic acid reflux faces several hurdles
8. Exposure to Agent Orange linked to prostate cancer in Vietnam veterans
9. A new cellular pathway linked to cancer is identified by NYU researchers
10. Sex and lifespan linked in worms
11. U of T discovers environmental factors linked to sex ratio of plants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... HUNTSVILLE, Ala. , March 2, 2015 /PRNewswire/ ... transaction processing. Data protection company Tharon Rankins Enterprises ... product that provides an ultra-safe way for businesses ... as their financial transactions. Beconux ... by Tharon Rankins Enterprises. Functioning similarly to an ...
(Date:2/24/2015)... This report analyzes the worldwide markets for Iris ... for the US, Canada , ... Asia-Pacific , Middle East , and ... are provided for the period 2013 through 2020. Also, a ... and analytics are derived from primary and secondary research. Company ...
(Date:2/23/2015)... , Feb. 23, 2015 NXT-ID, Inc. (NASDAQ: ... "Company"), a biometric authentication company focused on the growing ... provisional patent 62114357 for DISTRIBUTED VOICE DIRECTED ... NXT-ID introduces a new groundbreaking payment method. Payment accounts ... account may only be accessed if both the speech ...
Breaking Biology News(10 mins):Personal Data Protection Company Launches New Product 2World Iris Biometrics Industry 2World Iris Biometrics Industry 3World Iris Biometrics Industry 4World Iris Biometrics Industry 5World Iris Biometrics Industry 6World Iris Biometrics Industry 7World Iris Biometrics Industry 8World Iris Biometrics Industry 9World Iris Biometrics Industry 10World Iris Biometrics Industry 11NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3
... 2013 Disulfiram was the first medication approved for ... works, at least in part, by preventing the metabolism ... in the body quickly cause unpleasant symptoms, including nausea, ... a very strong incentive to avoid drinking. ...
... the fate of the original Otom inhabitants of Xaltocan, ... unknown. Researchers have long wondered whether they assimilated with ... to new anthropological research from The University of Texas ... the answers may lie in DNA. Following this line ...
... Thailand and Morocco have found that DHEA-S may prevent ... patients. In a report appearing in the February 2013 ... they describe how a network of steroid molecules found ... infection leading to brain damage. This suggests that treatment ...
Cached Biology News:Disulfiram: New support for an old addiction drug 2Aztec conquest altered genetics among early Mexico inhabitants, new DNA study shows 2A 'neurosteroid' found to prevent brain injury caused by HIV/AIDS 2
(Date:3/3/2015)... Ky. (PRWEB) March 03, 2015 Experts ... their schedules for one event: the Alltech REBELation exploring ... from May 17-20. Now in its 31st year, Alltech’s ... from 70 countries, and the opportunity to join the ... March 7 at 11:59 p.m. EST, at which point ...
(Date:3/3/2015)... March 3, 2015 /CNW/- SQI Diagnostics Inc. (TSX:V: SQD), ... technologies and products for advanced microarray diagnostics, today ... CFE  to its Management team. In his capacity ... its transition from a development stage to a ... advance the Company,s capital market strategy and to ...
(Date:3/3/2015)... March 3, 2015  Regenicin, Inc. (OTC Bulletin Board: ... the development of and commercialization of regenerative cell therapies ... announced today that it has received the final payment ... Holdings, Inc. (OTC Bulletin Board: AMBS ). ... made the final payments due to Regenicin in the ...
(Date:3/3/2015)... -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx") ... Opinion on Biological Therapy , Dr. Michael Chopp ... at the Henry Ford Hospital in Detroit, ... has the capacity to promote CNS and peripheral nervous ... to neurological recovery in each case.  They pointed out ...
Breaking Biology Technology:World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 2World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 3World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 4SQI Diagnostics Appoints Chief Financial Officer 2SQI Diagnostics Appoints Chief Financial Officer 3Regenicin (RGIN) Receives $2.3 Million in Final Payment from Amarantus 2Regenicin (RGIN) Receives $2.3 Million in Final Payment from Amarantus 3Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 2Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 3
... Sept. 8 Don Margolis, Chairman of,The Repair ... based in,Bangkok, Thailand told The Wall Street Transcript ... future profits inside the stem cell,research sector will ... five years, even for,companies specializing in Repair Stem ...
... 7th International ... Symposium on Uveitis in Germany, ZURICH, Switzerland, Sept. ... today announced that the,company has successfully completed its Phase I ... indications. In,April 2008, ESBATech initiated the Phase I study designed ...
... RNA levels, following 4 weeks of treatment with R7128 1500mg BID with Pegasys(R) plus ... Copegus(R) -, ... ... 8 Pharmasset, Inc.,(Nasdaq: VRUS ) announces the preliminary results of the fourth cohort ...
Cached Biology Technology:Stem Cell Profits Five Years Away, Says Repair Stem Cell Institute Chairman to The Wall Street Transcript 2ESBATech Announces Successful Completion of Phase I Clinical Study for Lead Antibody Fragment in Ophthalmic Indications 2Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders 2Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders 3Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders 4Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders 5Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders 6
...
...
Assay Diluent, 10 L...
... Immunogen: Synthetic peptide derived from ... junctophilin-3. Specificity: Specific for the ... Reactivity: Mouse (positive controls: mouse ... heart tissues). Applications: Western blotting ...
Biology Products: